{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"55.0","upperLimit":"71.2","value":"63.7"},{"groupId":"OG001","lowerLimit":"42.1","upperLimit":"58.8","value":"50.7"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.8","upperLimit":"50.4","value":"42.2"},{"groupId":"OG001","lowerLimit":"17.4","upperLimit":"31.7","value":"24.3"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.8","upperLimit":"35.8","value":"28.1"},{"groupId":"OG001","lowerLimit":"7.6","upperLimit":"18.7","value":"12.5"}]}],"title":"18 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"137"}],"units":"Participants"}],"description":"The overall survival rate is the probability that a participant will be alive at 6, 12, and 18 months following randomization. Overall survival was defined as the time between the date of randomization and the date of death as a result of any cause. Survival rates were determined via Kaplan-Meier estimates.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.","id":"OG000","title":"Nivolumab"},{"description":"Docetaxel 75mg/m\\^2 solution intravenously every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or study ends.","id":"OG001","title":"Docetaxel"}],"paramType":"NUMBER","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"Randomization to 18 months post-randomization, up to June 2015","title":"Overall Survival (OS) Rate in All Randomized Participants","type":"PRIMARY","unitOfMeasure":"Percent probability of OS"}